У нас вы можете посмотреть бесплатно Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert P... или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include: • Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy • Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapy • When to consider first-line treatment with immune checkpoint inhibitor monotherapy • Utility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapy Presenters: Georgios Gakis, MD Professor of Urology, Staff Urologist University Hospital of Würzburg Würzburg, Germany Mario Wolfgang Kramer, MD, PhD Consultant Urologist Vice Director, Urology University Hospital Schlewig-Holstein Campus Lübeck Lübeck, Germany Content based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc. Link to full program, including associated downloadable slidesets and on-demand webcast: https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.